Back
Rizzo_2022_MDPI_curroncol
Journal article

Stage III non-small-cell lung cancer : an overview of treatment options

  • Petrella, Francesco ORCID Department of Thoracic Surgery, European Institute of Oncology IRCCS, Milan, Italy - Department of Oncology and Hemato‐Oncology, University of Milan, Milan, Italy
  • Rizzo, Stefania ORCID Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Lugano, Switzerland - Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Attili, Ilaria Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy
  • Passaro, Antonio ORCID Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy
  • Zilli, Thomas Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Radiation Oncology, Oncological Institute of Southern Switzerland, EOC, Bellinzona, Switzerland - Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Martucci, Francesco Radiation Oncology, Oncological Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
  • Bonomo, Luca Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Lugano, Switzerland
  • Del Grande, Filippo ORCID Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Lugano, Switzerland - Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Casiraghi, Monica ORCID Department of Thoracic Surgery, European Institute of Oncology IRCCS, Milan, Italy - Department of Oncology and Hemato‐Oncology, University of Milan, Milan, Italy
  • De Marinis, Filippo Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy
  • Spaggiari, Lorenzo ORCID Department of Thoracic Surgery, European Institute of Oncology IRCCS, Milan, Italy - Department of Oncology and Hemato‐Oncology, University of Milan, Milan, Italy
Show more…
  • 2023
Published in:
  • Current oncology. - 2023, vol. 30 , no. 3, p. 3160-3175
Lung cancer
Stage III
Surgery
Medical treatment
Radiotherapy
English Lung cancer is the second-most commonly diagnosed cancer and the leading cause of cancer death worldwide. The most common histological type is non-small-cell lung cancer, accounting for 85% of all lung cancer cases. About one out of three new cases of non-small-cell lung cancer are diagnosed at a locally advanced stage—mainly stage III—consisting of a widely heterogeneous group of patients presenting significant differences in terms of tumor volume, local diffusion, and lymph nodal involvement. Stage III NSCLC therapy is based on the pivotal role of multimodal treatment, including surgery, radiotherapy, and a wide-ranging option of systemic treatments. Radical surgery is indicated in the case of hilar lymphnodal involvement or single station mediastinal ipsilateral involvement, possibly after neoadjuvant chemotherapy; the best appropriate treatment for multistation mediastinal lymph node involvement still represents a matter of debate. Although the main scope of treatments in this setting is potentially curative, the overall survival rates are still poor, ranging from 36% to 26% and 13% in stages IIIA, IIIB, and IIIC, respectively. The aim of this article is to provide an up-to-date, comprehensive overview of the state-of-the-art treatments for stage III non-small-cell lung cancer.
Collections
Language
  • English
Classification
Medicine
License
CC BY
Open access status
gold
Identifiers
Persistent URL
https://n2t.net/ark:/12658/srd1326720
Statistics
Document views: 35 File downloads:
  • Rizzo_2022_MDPI_curroncol.pdf: 113